Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6.
These kinases are involved in regulating progression through the cell cycle.
Mechanism of Action
CDK4 and CDK6 participate in phosphorylation processes involving the retinoblastoma protein pathway.
By inhibiting CDK4/6 activity, ribociclib can reduce progression through a key cell-cycle checkpoint.
This mechanism provides the biological basis for its role in certain hormone receptor-positive breast cancers.
Clinical Use
Ribociclib is used with endocrine therapy in clinically appropriate and approved treatment settings.
The exact indication can differ between countries and may change as regulatory information is updated.
Healthcare professionals should consult the current locally approved prescribing information.
Treatment Monitoring
Clinical monitoring can help identify:
- Hematologic toxicity
- Liver abnormalities
- Electrolyte abnormalities
- Cardiac electrical changes
- Drug interactions
Response Assessment
Treatment response may be assessed through methods appropriate to the patient’s cancer and clinical situation.
These may include:
- Clinical examination
- Imaging
- Laboratory assessment
- Evaluation of symptoms
The treating oncology team determines how response will be measured.
Treatment Decisions
Continuation, interruption, or modification of treatment depends on:
- Clinical response
- Side effects
- Laboratory findings
- Patient tolerance
- Overall treatment goals
Clinical decisions should be made by qualified healthcare professionals.